Suppr超能文献

方法 - 甲氨蝶呤治疗伴滑膜炎的手骨关节炎的随机对照试验:一项随机对照试验的研究方案。

METHODS - A randomised controlled trial of METhotrexate to treat Hand Osteoarthritis with Synovitis: study protocol for a randomised controlled trial.

机构信息

Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, VIC, 3004, Australia.

Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia.

出版信息

BMC Musculoskelet Disord. 2021 Nov 15;22(1):953. doi: 10.1186/s12891-021-04842-0.

Abstract

BACKGROUND

Hand osteoarthritis is a common and disabling problem without effective therapies. Accumulating evidence suggests the role of local inflammation in causing pain and structural progression in hand osteoarthritis, and hand osteoarthritis with synovitis is a commonly encountered clinical phenotype. Methotrexate is a well-established, low-cost, and effective treatment for inflammatory arthritis with a well-described safety profile. The aim of this multicentre, randomised, double-blind, placebo-controlled trial is to determine whether methotrexate reduces pain over 6 months in patients with hand osteoarthritis and synovitis.

METHODS

Ninety-six participants with hand osteoarthritis and synovitis will be recruited through the Osteoarthritis Clinical Trial Network (Melbourne, Hobart, Adelaide, and Perth), and randomly allocated in a 1:1 ratio to receive either methotrexate 20 mg or identical placebo once weekly for 6 months. The primary outcome is pain reduction (assessed by 100 mm visual analogue scale) at 6 months. The secondary outcomes include changes in physical function and quality of life assessed using Functional Index for Hand Osteoarthritis, Australian Canadian Osteoarthritis Hand Index, Health Assessment Questionnaire, Michigan Hand Outcomes Questionnaire, Short-Form-36, tender and swollen joint count, and grip strength, and structural progression assessed using progression of synovitis and bone marrow lesions from magnetic resonance imaging and radiographic progression at 6 months. Adverse events will be recorded. The primary analysis will be by intention to treat, including all participants in their randomised groups.

DISCUSSION

This study will provide high-quality evidence to address whether methotrexate has an effect on reducing pain over 6 months in patients with hand osteoarthritis and synovitis, with major clinical and public health importance. While a positive trial will inform international clinical practice guidelines for the management of hand osteoarthritis, a negative trial would be highly topical and change current trends in clinical practice.

TRIAL REGISTRATION

Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000877381. Registered 15 June 2017, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373124.

摘要

背景

手骨关节炎是一种常见且使人丧失能力的疾病,目前尚无有效的治疗方法。越来越多的证据表明,局部炎症在手骨关节炎引起疼痛和结构进展中起作用,并且伴有滑膜炎的手骨关节炎是一种常见的临床表型。甲氨蝶呤是一种成熟的、低成本且有效的治疗炎症性关节炎的药物,其安全性已得到充分描述。本多中心、随机、双盲、安慰剂对照试验的目的是确定甲氨蝶呤是否能在 6 个月内减轻患有滑膜炎的手骨关节炎患者的疼痛。

方法

通过骨关节炎临床试验网络(墨尔本、霍巴特、阿德莱德和珀斯)招募 96 名患有滑膜炎的手骨关节炎患者,并以 1:1 的比例随机分配,接受甲氨蝶呤 20mg 或相同的安慰剂,每周一次,持续 6 个月。主要结局是 6 个月时疼痛的减轻程度(通过 100mm 视觉模拟量表评估)。次要结局包括使用手部骨关节炎功能指数、加拿大-澳大利亚手部关节炎指数、健康评估问卷、密歇根手部结果问卷、36 项简短健康调查、压痛和肿胀关节计数以及握力评估的身体功能和生活质量的变化,以及使用磁共振成像的滑膜炎和骨髓病变进展以及 6 个月时的放射学进展评估的结构进展。将记录不良事件。主要分析将按照意向治疗进行,包括所有随机分组的参与者。

讨论

本研究将提供高质量的证据,以确定甲氨蝶呤是否在手骨关节炎和滑膜炎患者中具有减轻疼痛的作用,这对手部骨关节炎的临床和公共卫生具有重要意义。阳性试验将为手部骨关节炎的管理提供国际临床实践指南,而阴性试验将具有重要的时效性,并改变当前的临床实践趋势。

试验注册

澳大利亚新西兰临床试验注册中心(ANZCTR),ACTRN12617000877381。注册于 2017 年 6 月 15 日,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373124。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4acf/8594141/d1b0ad17365a/12891_2021_4842_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验